According to our results a new really promising simple, safe and cheap treatment option targeting mainly to the vascular net and the erythema of rosacea is proposed.
Wound healing and tissue regeneration are a field of clinical medicine presenting high research interest, since various local and systematic factors can inhibit these processes and lead to an inferior result. New methods of healing enhancement constantly arise, which, however, require experimental validation before their establishment in everyday practice. Platelet-rich plasma (PRP) is a well-known autologous factor that promotes tissue healing in various surgical defects. PRP derives from the centrifugation of peripheral blood and has a high concentration of growth factors that promote healing. Recently, the use of adipose-derived mesenchymal stem cells (ADMSCs) has been thoroughly investigated as a form of wound healing enhancement. ADMSCs are autologous stem cells deriving from fat tissue, with a capability of differentiation in specific cells, depending on the micro-environment that they are exposed to. The aim of the present comprehensive review is to record the experimental studies that have been published and investigate the synergistic use of PRP and ADMSC in animal models. The technical aspects of experimentations, as well as the major results of each study, are discussed. In addition, the limited clinical studies including humans are also reported. Future perspectives are discussed, along with the limitations of current studies on the long-term follow up needed on efficacy and safety.
Simplification of therapy is an option for many patients under antiretroviral therapy (ART). Regimens involving fewer drugs mean lower cost and a decrease in the pill burden, drug-drug interactions and side effects. 1 Currently, dual therapy including dolutegravir þ darunavir/cobicistat (DTGþDRV/c), boosted protease inhibitors (PIs) þ lamivudine, DTG þ rilpivirine have been studied with good results especially in treatment-naı¨ve patients and those already virologically suppressed on a three-drug regimen. 2 Meanwhile, concerns about maintenance of viral suppression with simplification therapy exist mainly in heavily-treated patients with a long history of therapy failures and now under successful salvage therapy. DTGþDRV/c is attractive as a salvage regimen for this population due to the absence of reverse transcriptase analogues, high genetic barrier and simplicity. 2,3 We report a retrospective study of a simplification strategy utilizing a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen comprising DTGþDRV/c. Our objective was to examine the efficacy and safety of this dual-drug simplification therapy among human immunodeficiency virus (HIV)-positive heavily pre-treated patients. Eligibility criteria included the administration of salvage ART, undetectable viral load (<20 copies/ml) for at least 12 months, more than one treatment failure due to treatment resistance in the past, multiple mutations in several drug categories and willingness of the patient to change therapy. Sixteen patients were included between March 2017 and January 2018 and received DTGþDRV/c once daily. All patients were men having sex with men with median age of 49 years. They were all under salvage therapy with !3 drugs from different antiretroviral classes, receiving 4-18 (median 7) pills/day and most of them (15/16) twice daily. These patients had been followed up for their HIV infection for 14 to 27 years (median 21 years).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.